FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3202192192> ?p ?o ?g. }

• W3202192192 endingPage "4514" @default.
• W3202192192 startingPage "4514" @default.
• W3202192192 abstract "There has recently been growing interest worldwide in biological therapies such as platelet-rich plasma injection for the treatment of knee osteoarthritis. However, predicting the effectiveness of platelet-rich plasma therapy remains uncertain. Therefore, this retrospective cohort study was performed to assess a range of predictors for the effectiveness of platelet-rich plasma therapy in treating knee osteoarthritis. The study included 517 consecutive patients who underwent three injections of leucocyte-poor platelet-rich plasma therapy from 2016 to 2019 at a single institution. The treatment outcomes, including patient-oriented outcomes (visual analogue scale score and Knee Injury and Osteoarthritis Outcome Score), were analyzed and compared according to the severity of knee osteoarthritis based on Kellgren-Lawrence (KL) grading using standing plain radiographs. Fisher's exact test, univariate regression, and multivariate regression were used for data analysis. Patient-oriented outcomes were significantly improved 6 and 12 months after platelet-rich plasma therapy. The overall responder rate in patients who met the Outcome Measures in Rheumatology (OMERACT)-Osteoarthritis Research Society International (OARSI) responder criteria was 62.1%. The responder rate was significantly lower in patients with severe knee osteoarthritis (KL4, 50.9%) than in those with mild (KL2, 75.2%) and moderate (KL3, 66.5%) knee osteoarthritis. The multivariate logistic regression analysis revealed that deterioration of the knee osteoarthritis grade (increased KL grade) was a significant predictor of a worse clinical outcome (odds ratio, 0.58; 95% confidence interval, 0.45-0.75; p < 0.001). The relative risk for non-responders in severe (KL4) KOA was 2.1 (95% CI, 1.5-3.0) at 6 months and 2.3 (1.6-3.2) at 12 months compared with mild-to-moderate (KL2-3) KOA. The efficacy of platelet-rich plasma therapy was not affected by age, sex, body weight, or platelet count. This study revealed that the effectiveness of platelet-rich plasma therapy for the treatment of knee osteoarthritis is approximately 60% and that the effectiveness depends on the severity of knee osteoarthritis. This observation is useful not only for physicians but also for patients with knee osteoarthritis." @default.
• W3202192192 created "2021-10-11" @default.
• W3202192192 creator A5005364471 @default.
• W3202192192 creator A5008196167 @default.
• W3202192192 creator A5018738941 @default.
• W3202192192 creator A5021002705 @default.
• W3202192192 creator A5045349650 @default.
• W3202192192 creator A5057460944 @default.
• W3202192192 creator A5059472238 @default.
• W3202192192 creator A5072038504 @default.
• W3202192192 creator A5082150027 @default.
• W3202192192 date "2021-09-29" @default.
• W3202192192 modified "2023-09-27" @default.
• W3202192192 title "Predictors of Effectiveness of Platelet-Rich Plasma Therapy for Knee Osteoarthritis: A Retrospective Cohort Study" @default.
• W3202192192 cites W1873023416 @default.
• W3202192192 cites W1967057044 @default.
• W3202192192 cites W1981688423 @default.
• W3202192192 cites W2006113857 @default.
• W3202192192 cites W2021796223 @default.
• W3202192192 cites W2057647525 @default.
• W3202192192 cites W2076653261 @default.
• W3202192192 cites W2099204150 @default.
• W3202192192 cites W2132844854 @default.
• W3202192192 cites W2155663618 @default.
• W3202192192 cites W2164916690 @default.
• W3202192192 cites W2490222838 @default.
• W3202192192 cites W2598207541 @default.
• W3202192192 cites W2752563562 @default.
• W3202192192 cites W2884783263 @default.
• W3202192192 cites W2896243120 @default.
• W3202192192 cites W2915030371 @default.
• W3202192192 cites W2955666772 @default.
• W3202192192 cites W2990507531 @default.
• W3202192192 cites W3000655318 @default.
• W3202192192 cites W3081830041 @default.
• W3202192192 cites W3134286095 @default.
• W3202192192 doi "https://doi.org/10.3390/jcm10194514" @default.
• W3202192192 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/8509123" @default.
• W3202192192 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34640529" @default.
• W3202192192 hasPublicationYear "2021" @default.
• W3202192192 type Work @default.
• W3202192192 sameAs 3202192192 @default.
• W3202192192 citedByCount "13" @default.
• W3202192192 countsByYear W32021921922021 @default.
• W3202192192 countsByYear W32021921922022 @default.
• W3202192192 countsByYear W32021921922023 @default.
• W3202192192 crossrefType "journal-article" @default.
• W3202192192 hasAuthorship W3202192192A5005364471 @default.
• W3202192192 hasAuthorship W3202192192A5008196167 @default.
• W3202192192 hasAuthorship W3202192192A5018738941 @default.
• W3202192192 hasAuthorship W3202192192A5021002705 @default.
• W3202192192 hasAuthorship W3202192192A5045349650 @default.
• W3202192192 hasAuthorship W3202192192A5057460944 @default.
• W3202192192 hasAuthorship W3202192192A5059472238 @default.
• W3202192192 hasAuthorship W3202192192A5072038504 @default.
• W3202192192 hasAuthorship W3202192192A5082150027 @default.
• W3202192192 hasBestOaLocation W32021921921 @default.
• W3202192192 hasConcept C126322002 @default.
• W3202192192 hasConcept C141071460 @default.
• W3202192192 hasConcept C142724271 @default.
• W3202192192 hasConcept C151956035 @default.
• W3202192192 hasConcept C156957248 @default.
• W3202192192 hasConcept C167135981 @default.
• W3202192192 hasConcept C198451711 @default.
• W3202192192 hasConcept C204787440 @default.
• W3202192192 hasConcept C2776164576 @default.
• W3202192192 hasConcept C2780076745 @default.
• W3202192192 hasConcept C44249647 @default.
• W3202192192 hasConcept C71924100 @default.
• W3202192192 hasConcept C72563966 @default.
• W3202192192 hasConcept C89560881 @default.
• W3202192192 hasConceptScore W3202192192C126322002 @default.
• W3202192192 hasConceptScore W3202192192C141071460 @default.
• W3202192192 hasConceptScore W3202192192C142724271 @default.
• W3202192192 hasConceptScore W3202192192C151956035 @default.
• W3202192192 hasConceptScore W3202192192C156957248 @default.
• W3202192192 hasConceptScore W3202192192C167135981 @default.
• W3202192192 hasConceptScore W3202192192C198451711 @default.
• W3202192192 hasConceptScore W3202192192C204787440 @default.
• W3202192192 hasConceptScore W3202192192C2776164576 @default.
• W3202192192 hasConceptScore W3202192192C2780076745 @default.
• W3202192192 hasConceptScore W3202192192C44249647 @default.
• W3202192192 hasConceptScore W3202192192C71924100 @default.
• W3202192192 hasConceptScore W3202192192C72563966 @default.
• W3202192192 hasConceptScore W3202192192C89560881 @default.
• W3202192192 hasIssue "19" @default.
• W3202192192 hasLocation W32021921921 @default.
• W3202192192 hasLocation W32021921922 @default.
• W3202192192 hasLocation W32021921923 @default.
• W3202192192 hasOpenAccess W3202192192 @default.
• W3202192192 hasPrimaryLocation W32021921921 @default.
• W3202192192 hasRelatedWork W2037611947 @default.
• W3202192192 hasRelatedWork W2138334887 @default.
• W3202192192 hasRelatedWork W2218945907 @default.
• W3202192192 hasRelatedWork W2335988042 @default.
• W3202192192 hasRelatedWork W2583387738 @default.
• W3202192192 hasRelatedWork W2971695752 @default.
• W3202192192 hasRelatedWork W3010075638 @default.

• next